March 2018 ASBMT Monthly Self-Directed Learning Quiz

On behalf of the ASBMT Committee on Education, we are pleased to continue our monthly self-directed learning quiz "Basic Principles and Practices of Hematopoietic Cell Transplantation and Cell Therapy – Question and Answer Approach” for fellows in training, highlighting HCT and cell therapy topics. Answers to each question appear with evidence-based “non-exhaustive” peer-review commentary. Our aim is to provide you with a credible and freely available educational resource. Questions generated and reviewed by Syed Abutalib, MD, Mark R. Litzow, MD, and William A. Wood, MD.

Question Title

* 1. Which of the following is the most consistent risk factor associated with progression of upper respiratory syncytial virus (RSV) respiratory tract infection to lower respiratory tract infection (RSV pneumonia) after hematopoietic cell transplantation?

A. Neutropenia

B. Lymphopenia

C. Cytomegalovirus seropositivity

D. Longer time to neutrophil engraftment

Question Title

* 2. Which of the following statements about respiratory syncytial virus (RSV) infection and its treatment is correct?

A. A large randomized trial has shown clear benefit using ribavirin for the treatment of RSV infection

B. The addition of immune globulin to ribavirin is an approved therapy

C. Transplant candidates with upper respiratory RSV infection can safely proceed with conditioning regimen

D. Respiratory secretions of any hospitalized transplant recipient who experiences signs or symptoms of RSV infection should be tested promptly by viral culture and rapid diagnostic test.

Question Title

* 3. Clinical cytomegalovirus (CMV) disease can be associated with which of the following problem(s)?

A. Gastroenteritis

B. Pneumonia

C. Hepatitis

D. Retinitis

E. All of the above

Question Title

* 4. Which of the following statements about cytomegalovirus (CMV) seroconversion and infection is correct?

A. Letermovir prophylaxis can result in lower risk of clinically significant CMV infection

B. Preemptive therapy with letermovir is an approved approach to reduce clinical CMV disease

C. Ganciclovir prophylaxis is clinically acceptable approach in allotransplant recipients

D. All of the above

Question Title

* 5. Letermovir prophylaxis versus placebo for cytomegalovirus (CMV) in hematopoietic cell transplantation by Marty and colleagues published in New England Journal of Medicine: Which of the following adverse effects was NOT observed in letermovir cohort?

A. Atrial fibrillation/flutter

B. Edema

C. Vomiting

D. Myelosuppression